ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

被引:2
|
作者
Linguanti, Flavia [1 ,2 ]
Abenavoli, Elisabetta Maria [3 ]
Calabretta, Raffaella [4 ]
Berti, Valentina [1 ]
Lopci, Egesta [5 ]
机构
[1] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Nucl Med Unit, I-50134 Florence, Italy
[2] Osped San Donato, Nucl Med Dept, I-52100 Arezzo, Italy
[3] Careggi Univ Hosp, Nucl Med Div, I-50134 Florence, Italy
[4] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Div Nucl Med, A-1090 Vienna, Austria
[5] IRCCS Humanitas Res Hosp, Nucl Med Unit, Via Manzoni 56, I-20089 Rozzano, Italy
关键词
ImmunoPET; PET/CT; receptor tyrosine kinases; RTK; EGFR; HER2; HER3; VEGF; METASTATIC BREAST-CANCER; ZIRCONIUM-89 LABELED CETUXIMAB; GROWTH-FACTOR RECEPTOR-3; PHASE-I; CU-64-DOTA-TRASTUZUMAB PET; ZR-89-BEVACIZUMAB PET; TRASTUZUMAB EMTANSINE; CELL CARCINOMA; HER3; RECEPTOR; EXPRESSION;
D O I
10.3390/cancers15245886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Receptor tyrosine kinases (RTKs) are a family of transmembrane proteins that play crucial roles in regulating various cellular processes. The introduction of ImmunoPET targeting RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer drugs. Herein, we review the current clinical research on ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.Abstract Receptor tyrosine kinases, or RTKs, are one large family of cell surface receptors involved in signal transduction, which represent an integral part of the signaling pathways. They play a crucial role in most important cellular processes, starting with the cell cycle, proliferation and differentiation, as well as cell migration, metabolism and survival. The introduction of ImmunoPET evaluating the expression of RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer therapeutics. Our review focuses mainly on the current clinical research regarding ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma
    Wirsik, Naita Maren
    Chen, Mingyi
    He, Liping
    Yasar, Uraz
    Gaukel, Justus
    Quaas, Alexander
    Nienhueser, Henrik
    Leugner, Ella
    Yuan, Shuai
    Schleussner, Nikolai
    Jung, Jin-On
    Pluecker, Jadie Sue
    Schneider, Martin
    Schmidt, Thomas
    CANCER MEDICINE, 2024, 13 (07):
  • [22] Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition
    Bozec, Alexandre
    Gros, Francois-Xavier
    Penault-Llorca, Frederique
    Formento, Patricia
    Cayre, Anne
    Dental, Clelia
    Etienne-Grimaldi, Marie-Christine
    Fischel, Jean-Louis
    Milano, Gerard
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (13) : 1922 - 1930
  • [23] Targeting epidermal growth factor receptor pathway with irreversible tyrosine kinase inhibitor
    Sagir, Fatma
    Demiroglu-Zergeroglu, Asuman
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2019, 44 (01): : 62 - 69
  • [24] Editorial: Targeting Bruton Tyrosine Kinase
    Brunner, Cornelia
    Betzler, Annika C.
    Brown, Jennifer R.
    Andreotti, Amy H.
    Grassilli, Emanuela
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [25] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
    Zhu, Chenjing
    Wei, Yuquan
    Wei, Xiawei
    MOLECULAR CANCER, 2019, 18 (01)
  • [26] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
    Chenjing Zhu
    Yuquan Wei
    Xiawei Wei
    Molecular Cancer, 18
  • [27] Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
    Guoshuang Shen
    Fangchao Zheng
    Dengfeng Ren
    Feng Du
    Qiuxia Dong
    Ziyi Wang
    Fuxing Zhao
    Raees Ahmad
    Jiuda Zhao
    Journal of Hematology & Oncology, 11
  • [28] Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
    Shen, Guoshuang
    Zheng, Fangchao
    Ren, Dengfeng
    Du, Feng
    Dong, Qiuxia
    Wang, Ziyi
    Zhao, Fuxing
    Ahmad, Raees
    Zhao, Jiuda
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [29] Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells
    Kamrani, Amin
    Mehdizadeh, Amir
    Ahmadi, Majid
    Aghebati-Maleki, Leili
    Yousefi, Mehdi
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (05) : 447 - 456
  • [30] MET Receptor Tyrosine Kinase
    Faoro, Leonardo
    Cervantes, Gustavo M.
    El-Hashani, Essam
    Salgia, Ravi
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : S1064 - S1065